Health Trials

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years

To evaluate the safety and Immunogenicity of 15-valent HPV vaccine in 9-45year-old participants.

Participants needed: 330
Trial details
Phase: Phase 2Age: 9-45Biological sex: AllType: InterventionalSponsor: Shanghai Bovax Biotechnology Co., Ltd.Updated: Dec 17, 2025Locations: 1
Eligibility criteria

Participants aged 9-45； [+6]

Have been vaccinated with other HPV vaccines or planned to vaccinate other HPV v... [+18]

Read more
Status: Recruiting

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years .

Participants needed: 8,000
Trial details
Phase: Phase 3Age: 20-45Biological sex: FemaleType: InterventionalSponsor: Shanghai Bovax Biotechnology Co., Ltd.Updated: Jun 7, 2024Locations: 1
Eligibility criteria

Chinese women aged 20-45 who can provide legal identification and have a sexual... [+6]

Have been vaccinated with commercially available HPV vaccine in the past or plan... [+34]

Read more
Status: Recruiting

Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine

To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.

Participants needed: 600
Trial details
Age: 9-45Biological sex: FemaleType: ObservationalSponsor: Shanghai Bovax Biotechnology Co., Ltd.Updated: Apr 17, 2024Locations: 2
Eligibility criteria

Subjects who participated in the phase III clinical trial of non inferior effica... [+3]

Enrolling or plan to enroll in other clinical trials (drugs or vaccines) (except... [+2]

Read more
Status: Recruiting

Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years

Participants needed: 1,348
Trial details
Phase: Phase 3Age: 9-26Biological sex: FemaleType: InterventionalSponsor: Shanghai Bovax Biotechnology Co., Ltd.Updated: Apr 17, 2024Locations: 1
Eligibility criteria

Healthy Chinese females aged 9 to 26 years; Provide legal identification; [+4]

Received marketed HPV vaccine or plan to receive marketed HPV vaccine during thi... [+16]

Read more